These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 26392492

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
    Bowker KE, Noel AR, MacGowan AP.
    J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
    [Abstract] [Full Text] [Related]

  • 4. Bactericidal activity and resistance development profiling of dalbavancin.
    Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
    Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263077
    [Abstract] [Full Text] [Related]

  • 6. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [Abstract] [Full Text] [Related]

  • 7. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M, Aguilar L, Sevillano D, Giménez MJ, Alou L, González N, Cafini F, Cleeland R, Prieto J.
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.
    Bowker KE, Noel AR, MacGowan AP.
    J Antimicrob Chemother; 2006 Oct; 58(4):802-5. PubMed ID: 16891629
    [Abstract] [Full Text] [Related]

  • 9. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [Abstract] [Full Text] [Related]

  • 10. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
    Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D, Nehr M, Ramharter M, Poeppl W, Makristathis A, Winkler S, Thalhammer F, Burgmann H, Lagler H.
    Emerg Microbes Infect; 2018 Dec 05; 7(1):202. PubMed ID: 30514923
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.
    Xhemali X, Smith JR, Kebriaei R, Rice SA, Stamper KC, Compton M, Singh NB, Jahanbakhsh S, Rybak MJ.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):82-86. PubMed ID: 30260409
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains.
    Citron DM, Tyrrell KL, Goldstein EJ.
    Diagn Microbiol Infect Dis; 2014 Aug 01; 79(4):438-40. PubMed ID: 24972854
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug 01; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 14. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C, Flammini S, Leonildi A, Ciullo I, Tagliaferri E, Menichetti F.
    J Chemother; 2012 Aug 01; 24(4):187-90. PubMed ID: 23040680
    [Abstract] [Full Text] [Related]

  • 15. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ, Jain R, Hahn A, Cummings L, Weaver T, Waalkes A, Sengupta D, Salipante SJ, Rakita RM, Butler-Wu SM.
    Clin Microbiol Infect; 2018 Apr 01; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [Abstract] [Full Text] [Related]

  • 16. Glycopeptide and daptomycin susceptibility trends among clinical isolates of methicillin-resistant Staphylococcus aureus in a tertiary care center in North India.
    Singh A, Prasad KN, Rai RP, Singh SK, Rahman M, Tripathi A, Srivastava JK.
    J Infect Public Health; 2015 Apr 01; 8(4):341-5. PubMed ID: 25797814
    [Abstract] [Full Text] [Related]

  • 17. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.
    Akins RL, Rybak MJ.
    Antimicrob Agents Chemother; 2000 Jul 01; 44(7):1925-9. PubMed ID: 10858356
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
    Moise PA, North D, Steenbergen JN, Sakoulas G.
    Lancet Infect Dis; 2009 Oct 01; 9(10):617-24. PubMed ID: 19778764
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
    Appleman MD, Citron DM.
    Diagn Microbiol Infect Dis; 2010 Apr 01; 66(4):441-4. PubMed ID: 20226335
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL, Kiffer CR, Mendes CM, Nicolau DP.
    Clin Microbiol Infect; 2008 Feb 01; 14(2):116-23. PubMed ID: 18076672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.